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Abstract
Background: Secondary hyperparathyroidism (SHPT) is associated with higher cardiovascular risk and mortality in
patients undergoing dialysis. Cinacalcet hydrochloride (CH), which has been clinically available in Japan since 2008, could
effectively reduce parathyroid hormone (PTH) levels even in patients with severe SHPT. However, parathyroidectomy
(PTx) is performed in patients with severe SHPT refractory to CH. This study investigated the effects of preoperative CH
treatment on the operative course and pathological findings of resected parathyroid glands (PTGs) in patients
undergoing PTx.
Methods: We retrospectively analyzed 194 PTx cases for SHPT in long-term hemodialysis patients at Showa University
Northern Yokohama Hospital from April 2002 to March 2014.
Results: A total of 45 patients were administered CH before PTx (CH group), and 149 patients never received CH
(non-CH group). No significant difference was seen in intact PTH levels, the number of resected PTGs, or operative time
between the two groups. However, the total volume of all PTGs and the volume of the largest PTG were significantly
lower in the CH than in the non-CH group. Patients with PTG adhesion to surrounding tissues were significantly more
prevalent in the CH than in the non-CH group. In addition, cystic changes or hemorrhagic necrosis in the resected PTGs
was observed more frequently in the CH group than in the non-CH group.
Conclusions: The results of the present study suggest that preoperative CH treatment might introduce pathological
changes in resected PTGs in PTx for severe SHPT, but it does not affect the operative time.
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Background
Secondary hyperparathyroidism (SHPT) frequently de-
velops in dialysis patients and is associated with various
complications in end-stage kidney disease [1–4]. In fact,
treatment of SHPT contributes to improved clinical out-
comes, including fracture, vascular calcification, cardio-
vascular events, and mortality. The prevention and
treatment of SHPT remain challenging for nephrologists.
Phosphate (P) management with dietary P restriction
and P binders, as well as vitamin D receptor activator
(VDRA) administration, is useful in the prevention and
management of SHPT [1–4]. However, severe SHPT re-
fractory to medical management may develop, leading to
the necessity of parathyroidectomy (PTx) for consider-
able numbers of dialysis patients [5–7].
In 2008, cinacalcet hydrochloride (CH), a calcimimetic
compound, became clinically available in Japan. CH is
effective in reducing serum parathyroid hormone (PTH)
levels even in patients with SHPT refractory to VDRA.
In fact, the incidence of PTx has dramatically decreased
in Japan since 2008 [5]. However, because of its adverse
gastrointestinal effects, the efficacy of CH in patients
with more severe SHPT or in those who cannot be ad-
ministered larger doses of CH is limited. CH has been
reported to reduce the size of hypertrophic parathyroid
glands (PTGs) in experimental and clinical studies [8–14].
Interestingly, CH may evoke cystic formation and he-
morrhagic necrosis in hypertrophic PTGs. Thus, CH
treatment might induce PTG adhesion to surrounding tis-
sues, which might then affect the PTx procedure [14]. Ac-
cordingly, this study investigated whether preoperative
CH treatment affects the pathological findings of resected
PTGs and the PTx procedure in hemodialysis (HD) pa-
tients with refractory SHPT.
Methods
We performed a retrospective observational study to
evaluate the effects of preoperative CH treatment on the
pathological findings of resected hypertrophic PTGs and
the intraoperative course in HD patients with refractory
SHPT who had undergone PTx between April 2002 and
March 2014. PTx was performed in cases refractory to
medical treatment. In general, refractory SHPT is
defined as intact PTH (iPTH) > 500 pg/mL or whole
PTH > 300 pg/mL, respectively, regardless of VDRA
and/or CH administration. It is also reasonable to con-
sider surgical PTx at lower PTH levels if it is difficult to
manage hyperphosphatemia or hypercalcemia with med-
ical treatment [15]. In the clinical guidelines published
by the Japanese Society for Dialysis Therapy (JSDT), the
target ranges for serum P, corrected calcium (Ca), and
iPTH concentrations are 3.5–6.0, 8.4–10.0, and 60–
240 pg/mL, respectively [15]. Patients who had previ-
ously undergone PTx or percutaneous ethanol injection
therapy were excluded. The indications for PTx for SHPT
were based on clinical and laboratory data according to
the JSDT guidelines [15]. All operative procedures were
performed by one surgeon (Y.K.) at Showa University
Northern Yokohama Hospital.
The patients were divided into CH and non-CH
groups. Patients who had been administered CH for at
least 4 weeks within 6 months before PTx were placed
in the CH group, while those who had never received
CH before PTx were placed in the non-CH group. We
compared preoperative data such as age, sex, HD vin-
tage, primary disease, and preoperative therapy with CH,
VDRA, and P binders. All blood samples for biochemical
measurements were collected within 1 week before PTx.
White blood cells (WBC), hemoglobin (Hb), platelets
(Plt), total protein (TP), albumin (Alb), serum urea
nitrogen (UN), creatinine (Cr), alkaline phosphatase
(ALP), Ca, P, and iPTH were measured using standard
methods. The measured serum Ca concentrations were
adjusted to Alb levels using the following equation: cor-
rected Ca = measured serum Ca concentration − serum
Alb concentration + 4.0.
We then compared the number of resected PTGs, their
estimated volume, their pathological findings (cyst forma-
tion [cystic lesions] and intraglandular hemorrhagic lesion
[hemorrhagic necrosis]), and operative course (operation
time, total intraoperative hemorrhage volume, and PTG
adhesion to surrounding tissues). PTG adhesion to sur-
rounding tissues was evaluated based on the operation
record written by the surgeons. All PTGs were gauged in-
traoperatively immediately after resection. We calculated
the estimated PTG volume using the following formula:
estimated PTG volume = π/6 × a × b × c (where a, b, and
c are the dimensions of the gland in centimeters). All
specimens were fixed in 10% formalin and embedded in
paraffin, and then, 4-μm-thick sections were stained with
hematoxylin-eosin. Histopathological studies of the PTGs
using light microscopy were performed in a blinded fash-
ion by a single investigator (A.T.). Hyperplasia was classi-
fied as either diffuse or nodular. Diffuse hyperplasia was
defined as an increased number of parenchymal cells with
normal lobular structures, while nodular hyperplasia was
defined as at least one well-circumscribed, encapsulated,
and virtually fat-cell-free accumulation of parenchymal
cells. Next, the presence of hemorrhagic necrosis and cys-
tic lesions was evaluated. Hemorrhagic necrosis was de-
fined as a hemorrhage filled with red blood cells and
observed inside the parenchyma of the hypertrophic nod-
ules. This study was approved by our institutional ethics
committee (no. 1507-09) and was performed in accord-
ance with the principles of the Declaration of Helsinki.
Continuous variables were expressed as means ± standard
deviation and categorical variables as frequencies, unless
noted otherwise. Statistical significances were determined
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by the χ2 test for categorical data. Differences between
groups were analyzed by Fisher’s exact test and t test for
categorical data and continuous variables, respectively.
Results
Study patients
A total of 194 patients were enrolled in the present study,
45 of whom had received CH for SHPT treatment (CH
group) before PTx (Fig. 1). Table 1 shows the clinical char-
acteristics of the study patients. The mean age of the en-
rolled patients was 55.3 ± 11.7 years, with women
representing 44.3% of the population (86 patients). The
average HD vintage was 13.0 ± 6.3 years. Although no sig-
nificant differences were observed in age, sex, or under-
lying diseases between the CH and non-CH groups, the
HD vintage in the CH group was significantly shorter than
that in the non-CH group (11.1 ± 5.7 vs. 13.6 ± 6.4 years,
respectively; P = 0.020). The preoperative laboratory data
are shown in Table 1. The WBC count was significantly
higher in the CH than in the non-CH group (5285 ± 1326
vs. 4805 ± 1253/μL, respectively; P = 0.027), and the
serum-corrected Ca concentration was significantly lower
in the CH than that in the non-CH group (9.7 ± 1.0 vs.
10.2 ± 0.8 mg/dL, respectively; P < 0.001). The Hb level,
Plt count, and serum concentrations of TP, Alb, UN, Cr,
ALP, P, and iPTH were comparable between the two
groups. The medication for chronic kidney disease-
mineral bone disorder (CKD-MBD) management included
P binders and VDRA. Although calcium carbonate
(CaCO3) was administered to 55.6% of the patients in the
CH and 45.0% of the patients in the non-CH group, re-
spectively, the difference was not statistically significant.
The mean CaCO3 dosage was similar in both groups.
Non-Ca-containing P binders were similarly administered
in the two groups. No significant differences were ob-
served between groups in the VDRA administration pat-
terns. The mean dosage of CH was 56.6 ± 25.5 mg/day in
the CH group on admission.
Resected PTGs
Although 761 PTGs were obtained from the 194 pa-
tients, we histologically evaluated 743 glands. Fourteen
glands could not be evaluated pathologically because
they were too small for pathological examination. The
number and estimated volume of all PTGs resected from
each patient were determined immediately after PTx in
the operating room. The numbers of resected PTGs did
not significantly differ between the two groups (Table 2).
The estimated volumes of all PTGs and the largest PTGs
were significantly lower in the CH than in the non-CH
group (1930.2 ± 1157.1 vs. 2526.9 ± 2524.7 mm3,
P = 0.028; and 1021.2 ± 737.7 vs. 1557.7 ± 2036.9 mm3,
P = 0.010, respectively) (Table 2). The ratio of nodular
hyperplasia and diffuse hyperplasia in resected PTGs
was similar in both groups (P = 0.168) (Table 3). Cystic
lesions and hemorrhagic necrosis of the resected PTGs
were observed significantly more frequently in the CH
than in the non-CH group (cystic lesions 30.2 vs. 22.8%,
P = 0.046; and hemorrhagic necrosis 23.8 vs. 13.1%,
P < 0.001, respectively). Semiquantitative analysis re-
vealed a significantly higher percentage of oxyphil cell
area relative to total area in the CH than in the non-CH
group (55.1% [95% confidence interval (CI) 51.3–59.8%]
vs. 38.2% [95% CI 33.7–48.8%], respectively; P = 0.011).
Next, we evaluated the relationship between resected
PTG volume and each histological change, including
nodular hyperplasia, hemorrhagic necrosis, and cystic le-
sions (Fig. 2a–d). For each histological change, the PTG
was significantly smaller in the CH than in the non-CH
group (Fig. 2b–d). In the CH group, the PTG volumes
were similar in nodular and diffuse hyperplasia (Fig. 2b).
Regardless of CH treatment, PTG with hemorrhagic ne-
crosis or cystic lesions was significantly larger than that
without (Fig. 2c, d).
In addition, we assessed the effect of the iPTH level dur-
ing the preoperative period on histological changes in the
PTGs. No difference was observed in cystic lesions or
hemorrhagic necrosis of the resected PTGs between pa-
tients with low PTH (minimum to median, 221–673 pg/mL
in the non-CH group and 83–476 pg/mL in the CH
group) and those with high PTH (median to maximum,
673–2616 and 476–2596 pg/mL, respectively), regardless
of CH treatment (Fig. 3a, b). However, CH treatment was
significantly associated with both cystic lesions and
hemorrhagic necrosis in patients with low PTH levels.
Interestingly, the prevalence of both pathologic changes
was comparable in patients with high PTH levels, regard-
less of CH treatment. No significant difference was
Fig. 1 Changes in the annual number of PTx procedures performed
for SHPT in Showa University Northern Yokohama Hospital. Since
the introduction of CH, the annual number of PTx procedures has
decreased. CH has been clinically available since 2008 in Japan. After
2009, most patients were previously treated with CH before PTx.
PTx parathyroidectomy, SHPT secondary hyperparathyroidism,
CH cinacalcet hydrochloride
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observed in PTG adhesion to surrounding tissues
between patients with low and high PTH levels,
regardless of CH treatment (Fig. 3c). However, CH
treatment significantly increased the prevalence of
PTG adhesion to surrounding tissues, regardless of
serum PTH level.
An analysis to assess the effect of CH dose immediately
before PTx on pathologic changes in the resected PTGs re-
vealed no differences in cystic lesions or hemorrhagic ne-
crosis between patients administered ≤ 50 or > 50 mg/day
CH (P = 0.9988 and P = 0.3729, respectively) (Fig. 4). In
addition, no significant difference was found in the
Table 1 Clinical, biochemical, and therapeutic characteristics of the study patients
All (n = 194) Non-CH group (n = 149) CH group (n = 45) P value
Age, years 55.3 ± 11.7 55.9 ± 11.7 53.3 ± 11.7 0.186
Female (%) 44.3 46.3 37.8 0.313
Dialysis vintage, years 13.0 ± 6.3 13.6 ± 6.4 11.1 ± 5.7 0.020
Underlying diseases (%)
CGN 54.1 55.0 51.1 0.747
DMn 8.8 7.4 13.3
Nephrosclerosis 6.7 6.7 6.7
PCK 8.8 8.1 11.1
Others 3.6 3.4 44.4
Unknown 18.0 19.5 13.3
WBC (/μL) 4916.6 ± 1283.2 4805.4 ± 1253.4 5284.9 ± 1325.9 0.027
Hb (g/dL) 10.6 ± 1.4 10.5 ± 1.4 10.8 ± 1.5 0.265
Plt (× 104/μL) 18. 2 ± 5.3 18.0 ± 5.1 18.8 ± 5.8 0.360
TP (g/dL) 6.3 ± 0.5 6.3 ± 0.5 6.3 ± 0.4 0.385
Alb (g/dL) 3.7 ± 0.3 3.7 ± 0.3 3.7 ± 0.3 0.183
SUN (mg/dL) 64.2 ± 16.5 64.9 ± 16.9 61.8 ± 14.9 0.286
Cr (mg/dL) 12.5 ± 3.0 12.5 ± 3.0 12.6 ± 2.9 0.841
ALP(U/L) 398.5 ± 284.3 386.1 ± 230.7 483.7 ± 413.5 0.419
corrected Ca (mg/dL) 10.1 ± 0.9 10.2 ± 0.8 9.7 ± 1.0 < 0.001
P (mg/dL) 6.3 ± 1.3 6.3 ± 1.3 6.0 ± 1.5 0.168
Intact PTH (pg/mL) 740.1 ± 408.1 764.6 ± 373.9 662.4 ± 498.5 0.210
CaCO3 (%) 47.4 45.0 55.6 0.213
(Dose g/day) 2.7 ± 1.9 2.6 ± 1.9 3.1 ± 1.7 0.252
Non-Ca containing P binders (%) 79.4 83.9 86.7 0.139
Oral VDRA (%) 4.1 4.0 4.4 0.902
Intravenous VDRA (%) 59.8 57.7 66.7 0.283
CH (%) 23.2 0 100 –
Data are presented as percentage or mean ± standard deviation
CGN chronic glomerulonephritis, DMn diabeteic nephropathy, PCK polycystic kidney disease, WBC white blood cell, Hb hemoglobin, Plt. Platelets, TP total protein,
Alb albumin, SUN serum urea nitrogen, Cr creatinine, ALP alkaline phosphatase, Ca calcium, P phosphate, PTH parathyroid hormone, VDRA vitamin D receptor
activator, CH cinacalcet hydrochloride
Table 2 Macroscopic characteristics of resected PTGs
All (n = 194) Non-CH group (n = 149) CH group (n = 45) P value
Number of resected PTGs 3.9 ± 0.4 3.9 ± 0.4 3.9 ± 0.4 0.854
Total volume of resected PTGs (mm3) 2388.5 ± 2292.8 2526.9 ± 2524.7 1930.2 ± 1157.1 0.028
Volume of the largest PTG (mm3) 1431.7 ± 1917.5 1557.7 ± 2036.9 1021.2 ± 737.7 0.010
Cases with adhesions (%) 8.8 4.7 22.2 < 0.001
Data are presented as percentage or mean ± standard deviation
PTG parathyroid gland, CH cinacalcet hydrochloride
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prevalence of PTG adhesion to surrounding tissues be-
tween these CH dosages (P = 0.4764) (Fig. 4).
We also assessed factors contributing to PTG adhe-
sion. Among the patient characteristics, only CH use
was significantly associated with adhesion in the resected
PTGs (Additional file 1: Table S1).
PTx procedure
Although the operative time did not significantly differ
between the two groups (non-CH group, median
112 min [95% CI 108–117] vs. CH group 103 min [95%
CI 95–112], P = 0.062), the volume of intraoperative
bleeding was significantly lower in the CH than in the
non-CH group (median 17.3 mL [95% CI 6.9–27.7] vs.
29.7 mL [95% CI 24.0–35.5), P = 0.040) (Fig. 5). Recur-
rent nerve palsy is the most common complication of
PTx. No significant difference was observed in the
prevalence of transient recurrent nerve palsy in the post-
operative period between groups (nine vs. four patients
in the non-CH and CH groups, respectively; P = 0.072).
Discussion
PTx has been demonstrated to significantly improve
clinical outcomes, including fracture, cardiovascular dis-
ease, and all-cause mortality [16–19] in patients with se-
vere SHPT. After CH became clinically available, the
rate of PTx for SHPT was greatly reduced [5–7]. This
study showed that the incidence of PTx for SHPT has
dramatically decreased in our hospital (Fig. 1). CH ef-
fectively decreases serum PTH levels, even in patients
with SHPT refractory to VDRA [8, 20]. However, a con-
siderable number of patients with severe SHPT cannot
be managed with medical treatment including CH and
VDRA, and PTx is therefore necessary for such patients.
In addition, PTx is superior to CH in terms of medical
economics. CH not only decreases serum PTH levels
but also suppresses PTG proliferation [9, 10]. CH treat-
ment has been demonstrated to reduce the volume of
hypertrophic PTGs in patients with SHPT [8, 11, 20].
The results of experimental studies suggest that calcimi-
metic compounds have the potential to provoke apop-
tosis in hypertrophic PTGs [21–23]. Thus, CH is likely
to induce pathological changes in hypertrophic PTGs,
including cystic changes, hemorrhagic lesions, or adhe-
sion to surrounding tissues. In this study, we assessed
whether CH treatment before PTx affected the patho-
logical findings of resected PTGs and PTx procedures in
HD patients with severe SHPT. The results revealed that
the number of resected PTGs was similar between the
two groups, but both the total volume of resected PTGs
and the volume of the largest gland were lower in pa-
tients with CH than in those without (Table 2). Micro-
scopic examination revealed that hemorrhagic necrosis
and cystic lesions were more prevalent in PTGs resected
from patients with CH than from those without
(Table 3). As previously reported [14], the oxyphil cell
area of the PTGs was significantly larger in the CH than
in the non-CH group. In nodular hyperplastic PTGs or
PTGs with hemorrhagic necrosis or cystic lesions, PTG
volume was significantly smaller in the CH than in the
non-CH group (Fig. 2). These results suggest that a re-
duction in PTG volume was associated with CH-
induced histopathological changes. In this study, we
assessed the effect of the preoperative PTH level on
histopathological changes in resected PTGs. PTH levels
did not affect the prevalence of cystic lesions or
hemorrhagic necrosis in resected PTGs, regardless of
CH treatment (Fig. 3). The prevalence of adhesion was
comparable between patients with low and high PTH
levels. In addition, the daily dose of CH did not affect
the prevalence of any histopathological changes in the
resected PTGs (Fig. 4).
Although the mean operative time was comparable be-
tween the two groups, the total volume of intraoperative
hemorrhage was significantly smaller in the CH than in
the non-CH group (Fig. 5). However, cases with PTG ad-
hesion to surrounding tissues were significantly more
frequent in the CH than in the non-CH group. This re-
sult was unexpected because CH-induced pathologic
changes in hypertrophic PTGs, including adhesion to
surrounding tissues, can complicate PTG removal. The
total volume of resected PTGs and the volume of the
largest PTG were significantly greater in the non-CH
than in the CH group. Therefore, a larger PTG size
Table 3 Histopathological changes of resected PTGs
All Non-CH group CH group P value
Total number of PTGs 743 571 172 0.417
Nodular hyperplasia 567 (76.3) 429 (75.1) 138 (80.2) 0.168
Diffuse hyperplasia 176 (23.7) 142 (24.9) 34 (19.8)
Cystic lesions 182 (24.5) 130 (22.8) 52 (30.2) 0.046
Hemorrhagic necrosis 116 (15.6) 75 (13.1) 41 (23.8) < 0.001
Oxyphil cell area, % 49.1 (43.4–50.4) 38.2 (33.7–48.8) 55.1 (51.3–59.8) 0.011
Data are expressed as the number (%) or median (95% confidential interval)
PTG parathyroid gland, CH cinacalcet hydrochloride
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Fig. 2 Representative photographs of hemorrhagic necrosis and
cystic lesions (a). The relationship between PTG volume and histological
changes, including nodular hyperplasia (b), hemorrhagic necrosis (c),
and cystic lesions (d), in samples resected from patients with or without
CH treatment. *P < 0.05 vs. PTG with each histological change, nodular
hyperplasia (b), hemorrhagic necrosis (c), or cystic lesion (d), not treated
with CH. #P < 0.05 vs. PTG with each histological change, nodular
hyperplasia (b), hemorrhagic necrosis (c), or cystic lesion (d), treated
with CH. PTG parathyroid gland, CH cinacalcet hydrochloride
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Fig. 3 Preoperative intact PTH levels and the prevalence of histological
changes, including cystic lesions (a), hemorrhagic necrosis (b), and
adhesion (c), in samples resected from patients with or without CH
treatment. Each PTH group was divided according to the median value
of intact PTH. *P < 0.05 vs. low PTH group without CH treatment.
#P < 0.05 vs. high PTH group without CH treatment. PTH parathyroid
hormone, CH cinacalcet hydrochloride
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might make resection more difficult. Consequently, the
total volume of intraoperative bleeding was significantly
greater in the non-CH than in the CH group, regardless
of PTG adhesion to surrounding tissues. All PTx proce-
dures were performed by a single surgeon (Y.K.) who
would have become more skillful over time. Most PTx
procedures in the non-CH group were performed
between 2002 and 2008 (Fig. 1); however, all PTx proce-
dures in the CH group were performed after 2009. This
result might be attributed to differences in the timing of
PTx between the two groups. The results reported by
relatively small studies lack consistency. Sumida et al. re-
ported that total PTG weight was comparable between
patients with and without CH treatment before PTx, but
the maximal PTG weight was significantly greater in pa-
tients with CH than in those without [14]. However, an-
other study showed that PTG weights were similar
between patients with and without CH treatment [24].
Factors other than preoperative CH treatment, including
disease duration of SHPT, P and Ca management, and
VDRA treatment, might affect PTG size. Vulpio et al. re-
ported that intraglandular hemorrhagic lesions were
more prevalent in patients with CH than in those with-
out [24]. Sumida et al. reported that the hemorrhagic
score of resected PTGs was comparable, but the hemosi-
derosis score was significantly higher in patients with
CH than in those without [14]. CH treatment is likely to
cause hemorrhagic changes in the hypertrophic PTGs of
SHPT. Doppler ultrasonographic studies have shown
that CH treatment induces reduced intraglandular vas-
culature and blood flow [12, 13].
This study did have some limitations. First, this was a
retrospective observational study; therefore, no causal
explanations are provided for the observed results. Sec-
ond, unselected variables might have affected the results.
Serum fibroblast growth factor-23 level, adherence to
a b c
Fig. 4 Effect of CH dose during the preoperative period on histological changes, including cystic lesions (a), hemorrhagic necrosis (b), and
adhesion (c). CH cinacalcet hydrochloride
0
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A Operative time, min B Total volume of intraoperative hemorrhage, mL
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Fig. 5 Effect of CH treatment on operative time (a) and total intraoperative hemorrhage volume (b). There was no significant difference in the
operative time between the non-CH and the CH group (median 112 min [95% CI 108–117] vs. 103 min [95% CI 95–112], P = 0.062) (a). The
volume of intraoperative bleeding was significantly lower in the CH than in the non-CH group (median 17.3 mL [95% CI 6.9–27.7] vs. 29.7 mL
[95% CI 24.0–35.5], P = 0.040) (b). CH cinacalcet hydrochloride, CI confidence interval
Takeshima et al. Renal Replacement Therapy  (2017) 3:49 Page 7 of 9
CH, differences in VDRA formulations (calcitriol or its
analogs), and individual anatomical structures of the
neck might be associated with the clinical cause of
SHPT, responsiveness to medical treatment, and the PTx
procedure. Third, as mentioned above, there were evi-
dent differences in the timing of PTx procedures be-
tween patients with and without CH. These differences
might have affected the results, including operative time
and operative hemorrhage volume. Fourth, we did not
have detailed data on the CH administration period be-
fore PTx because the CH-treated patients in this study
were defined as patients who had been administered CH
for at least 4 weeks within 6 months before PTx. The ad-
ministration period of CH might affect the histological
changes in hypertrophic PTGs in patients with SHPT.
Recently, a new calcimimetic compound, etelcalcetide,
has become clinically available in the USA and Japan.
Etelcalcetide is expected to be administrated in patients
who cannot be administered CH because of gastrointes-
tinal symptoms. Therefore, greater numbers of patients
with SHPT are expected to be treated with calcimimetic
compounds. It will be of interest to investigate whether
etelcalcetide provokes any histological changes in hyper-
trophic PTGs in patients with SHPT.
Conclusions
The results of this study suggest that both the total vol-
ume of resected PTGs and the volume of the largest PTG
were significantly smaller in patients with than in patients
without CH treatment before PTx. Pathological examina-
tions revealed that CH treatment was significantly associ-
ated with hemorrhagic necrosis and cystic lesions of the
resected PTGs. Although operative time was comparable
between patients with and without CH treatment, the vol-
ume of intraoperative hemorrhage was significantly
smaller in the CH than in the non-CH group.
Additional file
Additional file 1: Table S1. Characteristics of patients with or without
adhesion lesions in resected PTGs. (PPTX 54 kb)
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